NASDAQ · Healthcare · Biotechnology
Larimar Therapeutics, Inc.
LRMR
Larimar Therapeutics, Inc. CEO Carole S. Ben-Maimon · Market cap $350.0M.
$4.09
+0.12 · +3.02%
52w hi $6.4252w lo $1.73
Off 52w high 29.3%
88
STRONG
Current InsiderScore
Corp · 90d
7
7 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
10
7 strong · 3 notable
Analyst consensus
Strong Buy
Avg PT $12.00
Section 01
Recent Form 4 filings
10 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Feb 27 | James E Flynn | Buy | 2,000,000 | $5.00 | +$10.00M | 88 | |
| Feb 27 | James E Flynn | Buy | 1,084,010 | $5.00 | +$5.42M | 84 | |
| Feb 27 | James E Flynn | Buy | 1,084,012 | $5.00 | +$5.42M | 84 | |
| Feb 27 | Thomas Edward Hamilton | Buy | 100,000 | $5.00 | +$500K | 71 | |
| Feb 27 | Jeffrey W Sherman | Buy | 5,000 | $5.00 | +$25K | 73 | |
| Feb 27 | Frank E Thomas | Buy | 5,000 | $5.00 | +$25K | 73 | |
| Feb 27 | James E Flynn | Buy | 831,978 | $5.00 | +$4.16M | 81 | |
| Jul 31 | James E Flynn | Buy | 3,387,539 | $3.20 | +$10.84M | 76 | |
| Jul 31 | James E Flynn | Buy | 2,599,932 | $3.20 | +$8.32M | 76 | |
| Jul 31 | James E Flynn | Buy | 3,387,529 | $3.20 | +$10.84M | 76 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
JunJulAugSepOctNovDecJanFebMarAprMay